Novavax Inc on Thursday started a late-stage trial of its experimental COVID-19 vaccine in partnership with the UK government’s Vaccines Taskforce, sending the company’s shares up 6% after the bell.
The trial is expected to enroll and test the vaccine in up to 10,000 participants aged between 18 and 84 years over the next four to six weeks.
Data from the trial will support regulatory submissions for license in the UK, EU and other countries, the company said.
The study has two main goals, the first occurrence of PCR-confirmed symptomatic COVID-19 at least 7 days after the second study vaccination in volunteers who have not been previously infected with SARS-CoV-2. The second main goal is first occurrence of PCR-confirmed symptomatic moderate or severe COVID-19 at least 7 days after the second study vaccination in volunteers who have not been previously infected with the virus.
The trial will enroll at least 25% of participants over the age of 65 and prioritize groups most affected by the COVID-19, the company said.
A letter from the Editor
Dear reader,
We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.
Support Quality Journalism
A letter from the Editor
Dear subscriber,
Thank you!
Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.
The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.
We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.
Suresh Nambath